Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide
Therapeutic Advances in Cardiovascular Disease · 2026-08 · 20
DOI: 10.1177/17539447261478928 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 17.08.2026. Verfasst von Ibrahim Mortada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA. Hauptthemen laut MEDLINE: Tirzepatide, Obesity, Heart Failure, Stroke Volume. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, UTMB Institute for Translational Sciences.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sex-related differences are well recognized in heart failure with preserved ejection fraction (HFpEF), but real-world data describing clinical outcomes by sex among patients with obesity and HFpEF treated with tirzepatide remain limited.
Objectives
To compare observed hospitalization, cardiovascular, and gastrointestinal outcomes between male and female patients with obesity and HFpEF treated with tirzepatide.
Design
Retrospective, propensity score-matched, within-treatment cohort study.
Methods
A retrospective study was conducted using TriNetX database which included 110 healthcare organizations. Adults with obesity, HFpEF, and taking tirzepatide between June 1, 2022 and January 1, 2025 were identified. Males and females were balanced using 1:1 propensity score matching (n=1,654 per group). Primary outcome assessed included all-cause hospitalization. Secondary outcomes were all-cause mortality, HF exacerbation, major adverse cardiovascular events (MACE), incident atrial fibrillation, nausea/vomiting and diarrhea. Two prespecified falsification endpoints were used.
Results
During 1-year follow-up, males had a lower hazard of all-cause hospitalization compared with females (HR 0.87, 95% CI 0.77–0.98). No significant differences were observed for all-cause mortality (HR 1.73, 95% CI 0.95–3.18), HF exacerbation (HR 1.14, 95% CI 0.90–1.44), MACE (HR 1.28, 95% CI 0.99–1.65), or incident atrial fibrillation (HR 1.21, 95% CI 0.61–2.43). Males experienced lower rates of nausea and vomiting (HR 0.50, 95% CI 0.37–0.67), while diarrhea was similar (HR 0.84, 95% CI 0.59–1.19). Falsification endpoints showed no significant associations.
Conclusion
Among tirzepatide-treated patients with obesity and HFpEF, no statistically significant sex-associated differences were detected in major cardiovascular outcomes. Males had a modestly lower observed hazard of hospitalization and fewer coded nausea and vomiting events. Because this was a within-treatment observational comparison without an external comparator, these findings should not be interpreted as evidence of differential tirzepatide effectiveness by sex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- Department of Emergency Medicine, University of Texas Medical Branch, Galveston, TX, USA.
ORCID-Profile: Ibrahim Mortada, Aaron W Lee, Dalton Buckingham, Valerie Quach, Shareef Mansour, Khaled Chatila, Mostafa Shalaby, Dietrich Jehle, Michael C Boyars, Thomas A Blackwell, Hani Jneid
Förderung
- NCATS NIH HHS
- UTMB Institute for Translational Sciences
Zitieren
APA
Mortada, I., Lee, A. W., Buckingham, D., Quach, V., Rice, J., Mansour, S., Chatila, K., Shalaby, M., Jehle, D., Boyars, M. C., Blackwell, T. A., & Jneid, H. (2026). Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide. Therapeutic Advances in Cardiovascular Disease, 20. https://doi.org/10.1177/17539447261478928
Vancouver
Mortada I, Lee AW, Buckingham D, Quach V, Rice J, Mansour S, et al. Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide. Therapeutic Advances in Cardiovascular Disease. 2026;20. doi:10.1177/17539447261478928
BibTeX
@article{Mortada2026,
author = {Mortada, Ibrahim and Lee, Aaron W and Buckingham, Dalton and Quach, Valerie and Rice, James and Mansour, Shareef and Chatila, Khaled and Shalaby, Mostafa and Jehle, Dietrich and Boyars, Michael C and Blackwell, Thomas A and Jneid, Hani},
title = {Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide},
journal = {Therapeutic Advances in Cardiovascular Disease},
year = {2026},
volume = {20},
doi = {10.1177/17539447261478928}
}
EUVIMED